CHE Q3 CY2025 Deep Dive: Margin Pressure Persists Despite Operational Progress in Core Segments
Update: 2025-10-30
Description
Chemed Corporation's Q3 results show mixed performance: sales up 3.1% to $624.9M, matching expectations, but adjusted earnings per share at $5.27, slightly below estimates. Operating margin slipped to 12% from 15.2% last year due to challenges at VITAS and Roto-Rooter. VITAS faced higher costs from hospital admissions, while Roto-Rooter spent more on paid leads. Despite market concerns, management sees a positive end to the year with seasonal boosts and efficiency improvements. Analysts will monitor VITAS' hospital admissions and Roto-Rooter's margin growth. Chemed's shares have risen post-report, indicating investor confidence in their growth strategy.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
